Teva Pharma (TEVA) volatility flat into Mylan (MYL) granted FDA approval of Copaxone
Tweet
Share
E-mail
Get Alerts TEVA Hot Sheet
Price: $36.36 -0.71%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.1%
EPS Growth %: -10.3%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.1%
EPS Growth %: -10.3%
Join SI Premium – FREE
Teva (NYSE: TEVA) October weekly call option implied volatility is at 40, October is at 41, November is at 47; compared to its 52-week range of 24 to 61 into Mylan (Nasdaq: MYL) was granted FDA approval of the first generic for Copaxone.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teva Pharma (TEVA) PT Raised to $48 at UBS
- Western Digital (WDC) call put ratio 1.1 calls to 1 put as share price up 4.2%
- SK Hynix (SKHY) call put ratio 1.4 calls to 1 put as share price up 3.8%
Create E-mail Alert Related Categories
Options, Trader TalkRelated Entities
Options, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
